2025-09-19 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the provided data, presented in English with numerical highlights and summaries, along with interpretations:

**Report on Teladoc Health Inc. (TDOC)**

**0. Overview**

This report analyzes Teladoc Health Inc. (TDOC) based on various performance metrics, market indicators, recent news, and analyst opinions.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TDOC
*   **Company:** Teladoc Health Inc. (Provides virtual healthcare services.)
*   **TDOC Cumulative Return:** -60.97%
*   **VOO Cumulative Return:** 107.08%
*   **Disparity:**
    *   **Absolute:** -168.05% (TDOC significantly underperformed the S&P 500)
    *   **Range:** Max: 456.6, Min: -169.3, Current: -169.3
    *   **Relative Disparity:** 0.0 (This indicates the disparity is at the lowest end of its historical range, meaning TDOC is performing at its worst relative to VOO within the given period).

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha    | Beta     | Cap(B) |
| :----------- | :------- | :------- | :------- | :------- | :------- |
| 2015-2017  | 76.0%    | 60.6%    | 50.0%    | -0.0     | 6.2      |
| 2016-2018  | 128.0%   | 59.3%    | 110.0%   | -0.0     | 8.8      |
| 2017-2019  | 176.0%   | 59.3%    | 147.0%   | 0.4      | 14.8     |
| 2018-2020  | 237.0%   | 64.0%    | 217.0%   | 0.1      | 35.3     |
| 2019-2021  | -83.0%   | 64.0%    | -132.0%  | 0.1      | 16.2     |
| 2020-2022  | -295.0%  | 81.3%    | -297.0%  | 0.0      | 4.2      |
| 2021-2023  | -488.0%  | 81.3%    | -506.0%  | -0.6     | 3.8      |
| 2022-2024  | -111.0%  | 81.3%    | -137.0%  | -0.8     | 1.6      |
| 2023-2025  | -32.0%   | 75.5%    | -90.0%   | -0.8     | 1.5      |

*   **Analysis:**
    *   **CAGR & MDD:** The table shows a drastic decline in CAGR over the later periods. The Maximum Drawdown (MDD) has remained relatively high, indicating significant risk.
    *   **Alpha:** Alpha is consistently negative in recent years, showing underperformance relative to the market.
    *   **Beta:** Beta is low and even negative in some periods, indicating low correlation with the market.
    *   **Capitalization:** Market capitalization has decreased substantially in recent years.

**2. Recent Price Action**

*   **Current Price:** $8.26
*   **Last Market Data:** Price: $8.26, Previous Close: $7.90, Change: 4.56% (Significant positive change)
*   **Moving Averages:**
    *   5-day: $7.876
    *   20-day: $7.7443
    *   60-day: $7.7893

*   **Analysis:** The recent price surge is evident, with the current price above all three moving averages, suggesting short-term bullish momentum.  The significant change from the previous close reinforces this.

**3. Market Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3324 (Low Risk)
*   **RSI:** 59.54 (Approaching overbought territory)
*   **PPO:** 0.5554 (Positive, indicating bullish momentum)
*   **Hybrid Signal:** "cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)" (Suggests a buy signal but with caution due to MRI)
*   **Recent (20-day) Relative Disparity Change:** -0.4 (Negative – Short-term decline)
*   **Expected Return:** -10400.4% (Very negative, suggesting significant long-term underperformance vs. S&P 500)

*   **Analysis:** The MRI indicates low market risk. The RSI is approaching overbought territory. The PPO is positive, supporting bullish momentum. The large positive 'change' (4.56%) in the Last-market data reflects a notable price increase, possibly due to recent news or market sentiment shift. However, the extremely negative expected return is a major concern.

**4. Recent News & Significant Events**

*   **[2025-09-17]** Berkshire Hathaway Specialty Insurance Enters the Accident & Health Market in the UK
*   **[2025-09-16]** Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know
*   **[2025-09-16]** Hims & Hers Expands AI and Technology Focus to Advance Digital Care
*   **[2025-09-15]** Transcarent Appoints Dr. Alan Roga as Chief Clinical Officer
*   **[2025-09-12]** Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?
*   **[2025-09-10]** Teladoc (TDOC) Stock Drops Despite Market Gains: Important Facts to Note

*   **Analysis:**  The news is mixed. While one article highlights TDOC's increase despite a market slip, another mentions a drop despite market gains, showing volatility. News regarding competitors like Hims & Hers expanding their AI focus is relevant as it signals increasing competition in the telehealth space.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.64 (~Hold)
*   **Opinions:** 20
*   **Target Price:** Avg: $9.12 / High: $12.00 / Low: $7.00
*   **Recent Rating Changes:** No changes provided

*   **Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook. The average target price is slightly above the current price, indicating modest upside potential.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
| :--------- | :---- | :------- |
| 2025-07-30 | -0.19 | 0.63 B$  |
| 2025-05-01 | -0.53 | 0.63 B$  |
| 2024-10-31 | -0.19 | 0.64 B$  |
| 2024-08-01 | -4.92 | 0.64 B$  |
| 2025-07-30 | -4.92 | 0.64 B$  |

*   **Analysis:** TDOC has been reporting losses (negative EPS). Revenue has remained relatively stable around $0.63-0.64 billion. The significant loss in 2024-08-01 is repeated in 2025-07-30 and this is a major concern, and it seems like there is some abnormal issue.

**6. Financial Information**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-06-30 | $0.63B   | 69.85%       |
| 2025-03-31 | $0.63B   | 68.73%       |
| 2024-12-31 | $0.64B   | 70.50%       |
| 2024-09-30 | $0.64B   | 71.94%       |
| 2024-06-30 | $0.64B   | 70.73%       |

| Quarter    | Equity    | ROE       |
| :--------- | :-------- | :-------- |
| 2025-06-30 | $1.42B   | -2.30%    |
| 2025-03-31 | $1.43B   | -6.52%    |
| 2024-12-31 | $1.49B   | -3.25%    |
| 2024-09-30 | $1.51B   | -2.21%    |
| 2024-06-30 | $1.50B   | -55.77%   |

*   **Analysis:** Revenue is consistent.  Profit margins are strong, in the 68-72% range. However, Equity is decreasing, and ROE is consistently negative, indicating the company is not generating profits from its equity.

**7. Overall Summary**

Teladoc Health Inc. (TDOC) has significantly underperformed the S&P 500. Recent price action shows a short-term bullish trend.  However, analyst consensus is neutral ("Hold"). Earnings data reveals ongoing losses (negative EPS). While revenue remains stable and profit margins are high, declining equity and negative ROE raise concerns. The extremely negative expected return suggests long-term underperformance relative to the market. The news flow is mixed, reflecting the company's volatile performance. The significant positive 'change' (4.56%) in the Last-market data reflects a notable price increase, possibly due to recent news or market sentiment shift.

**In conclusion, while there may be short-term trading opportunities, significant fundamental concerns remain regarding TDOC's long-term profitability and ability to generate shareholder value. The significant loss in 2024-08-01 is repeated in 2025-07-30 and this is a major concern, and it seems like there is some abnormal issue.**
